Drug Discovery & Pharmaceuticals

RSS

Cellectricon’s expertise in pain research recognized by second EU research grant

BonePainIII project will support an early-stage researcher in quest for novel mechanistic insight and potential therapeutic targets.

From Cellectricon 19 Feb 2024

Novel synthetic antibiotic effective against drug-resistant bacteria

A new antibiotic created by Harvard researchers overcomes antimicrobial resistance mechanisms that have rendered many modern drugs ineffective and are driving a global public health crisis.

15 Feb 2024

Breaking through new research barriers with iPSC technology

In this interview, we speak to Keith Olson and Coby Carlson from Fujifilm Cellular Dynamics about their iPSC technology.

From FUJIFILM Cellular Dynamics 15 Feb 2024

Academia's drug discovery challenges: Exploring the "publication landfill"

A new editorial paper was published in Oncotarget's Volume 15 on January 24, 2024, entitled, "The fate of drug discovery in academia; dumping in the publication landfill?"

6 Feb 2024

Hamamatsu introduces the New FDSS-GX: the highest-performance kinetic plate imager in the FDSS series

Hamamatsu Photonics announces the release of a new high-speed kinetic plate imager, the FDSS-GX.

From Hamamatsu Photonics Europe 5 Feb 2024

SCIEX expands high-throughput screening solutions with Echoâ MS+ system

The Echo® MS+ system unlocks enhanced high-throughput screening capability by bringing acoustic ejection mass spectrometry (AEMS) approaches to the SCIEX ZenoTOF 7600 system.

From SCIEX 5 Feb 2024

Almirall and Microsoft partner on AI-powered drug discovery in dermatology

Almirall S.A., a global pharmaceutical company focused on medical dermatology, announced today a strategic partnership with Microsoft to drive innovation and digital transformation, advance the research of medical solutions for dermatological diseases, and accelerate the digital transformation of the company.

5 Feb 2024

New molecule is one step closer to becoming a treatment for Phelan-McDermid syndrome

A molecule created at the University of Auckland is one step closer to becoming a treatment for an extremely rare and severely debilitating neurological disorder called Phelan-McDermid syndrome.

2 Feb 2024

Researchers discover non-opioid therapeutic for relieving neuropathic pain

Among the most difficult types of pain to alleviate is neuropathic pain, pain that is usually caused by damage to nerves in various body tissues, including skin, muscle and joints.

31 Jan 2024

CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market

CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the appointment of Joseph Parisi as US Director of Sales. In his new role, Joe will lead the expansion of the Company’s sales and support activities for the US market to address the growing demand for new alternative methodologies (NAMs) in preclinical drug discovery.

31 Jan 2024

Enterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financing

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.

From Enterprise Therapeutics Ltd 31 Jan 2024

New DNA-based vaccine can induce strong antibody response against SARS-CoV-2

Using a virus-like delivery particle made from DNA, researchers from MIT and the Ragon Institute of MGH, MIT, and Harvard have created a vaccine that can induce a strong antibody response against SARS-CoV-2.

30 Jan 2024

New study opens unprecedented opportunities for bioengineering vaccine adjuvants

A valuable molecule sourced from the soapbark tree and used as a key ingredient in vaccines, has been replicated in an alternative plant host for the first time, opening unprecedented opportunities for the vaccine industry.

26 Jan 2024

CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies

CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.

24 Jan 2024

C-Path's TRxA launches 2024 grants to boost next-gen therapeutics

Critical Path Institute's (C-Path) Translational Therapeutics Accelerator (TRxA) today announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants, also known as BRIDGe.

23 Jan 2024

Moffitt researchers develop novel reagent for efficient synthesis of sulfur-containing drug candidates

During the past decade, there has been significant development of new sulfur containing compounds that are used in various industries, including pharmaceuticals and agricultural products.

22 Jan 2024

AI scores breakthrough in anemia treatment with novel PHD inhibitor

Clinical stage generative artificial intelligence (AI)-driven biotechnology company InSilico Medicine ("InSilico"), today announced that the Journal of Medicinal Chemistry, an ACS Publications journal focusing on critical studies about molecular structure and biological activity, has published the company's discovery of a novel PHD inhibitor for the treatment of anemia.

19 Jan 2024

Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1.

19 Jan 2024

Conscience's open science competition yields hits for new Parkinson's drugs

As part of its pioneering approach to drug discovery, the Canadian nonprofit Conscience announced today that its first open science competition has resulted in the identification of seven promising molecules, or "hits," that show potential for new, more effective drugs for familial Parkinson's disease.

16 Jan 2024

New analysis of cancer cells identifies 370 targets for smarter, personalized treatments

A new, systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types, including breast, lung and ovarian cancers.

13 Jan 2024